Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)

Base rate is below 50% here. This is a Phase 2 dose-ranging study in sepsis-associated acute kidney injury, a highly heterogeneous ICU syndrome with rapid clinical swings and a long history of efficacy disappointments. The primary endpoint is a short-term renal function surrogate: time-corrected creatinine-clearance AUC over Days 1-8. That can improve statistical sensitivity versus hard outcomes, but it is also vulnerable to substantial noise from urine collection quality, fluid balance, hemodynamics, baseline renal reserve, and nonsteady creatinine kinetics in septic patients. The study tests three single doses, which is useful for dose-response learning, yet a one-time biologic intervention may struggle to produce a robust, durable signal across such a mixed population. Positives are the placebo control, formal dose-ranging design, and a large-cap sponsor likely to execute operations and data handling well. Overall, the trial is capable of showing pharmacologic activity, but indication difficulty and endpoint variability make a clearly positive readout more likely to miss than succeed.

TIN816 is a novel recombinant CD39 enzyme targeting ATP/ADP hydrolysis in SA-AKI, an indication with no approved pharmacologic treatments and a notoriously high failure rate in clinical trials. The Phase 2a study (n=20) showed acceptable PK and safety, but biomarker signals supporting pathway engagement were limited by small sample size and variability, with changes seen in both TIN816 and placebo arms. Preclinical models showed dose-dependent protection, but translating sepsis animal models to human efficacy is historically unreliable. The Phase 2b is a dose-finding study across 3 dose levels (1, 2, 4 mg/kg) versus placebo in ~320 patients with a continuous primary endpoint (AUC creatinine clearance Day 1-8), which is a relatively sensitive biomarker endpoint favorable for detecting signals. However, the critically ill ICU population introduces enormous variability and high placebo-group recovery rates. The REVIVAL trial of a comparable compound (ilofotase alfa/alkaline phosphatase) failed its Phase 3 primary endpoint despite promising Phase 2 results. SA-AKI trials have a poor track record. The trial is past primary completion with no results disclosed yet, suggesting possible null or complex results. I estimate ~30% probability of positive results.

This is a Phase 2b study in sepsis-associated acute kidney injury (SA-AKI), a notoriously difficult indication with high failure rates. The trial tests TIN816, a biologic with no prior efficacy data visible in the trial fields. While Novartis is an experienced sponsor and the primary endpoint (creatinine clearance AUC over 8 days) is objective and clinically meaningful, Phase 2 trials in critical care settings like SA-AKI face substantial challenges including patient heterogeneity, complex pathophysiology, and high background event rates. The study is 36 days past its primary completion date, suggesting data may be imminent, but without prior proof-of-concept data, the baseline probability of a positive outcome remains low. Most early-phase biotech trials fail to meet their primary endpoints, particularly in this complex indication.

This is a well-designed Phase 2b dose-finding study by a major sponsor (Novartis) in a high-unmet-need ICU population with sepsis-associated AKI. The primary endpoint, AUC of creatinine clearance over 8 days, is a clinically relevant and continuous measure of kidney function recovery, superior to binary outcomes. The trial is complete (Active Not Recruiting, primary completion date passed 36 days ago), reducing operational risk. However, the intrinsic probability is only modestly above 50% due to the high-risk patient population, the challenging pathophysiology of SA-AKI, and the fact this is a first efficacy signal for this specific biological agent in this setting. Prior data is not provided, adding uncertainty. The endpoint is robust but success requires a clear dose-response.

Phase 2b dose-response trial tests three single doses of TIN816 (biologic) vs placebo in ICU adults with sepsis-associated AKI, a severe, heterogeneous condition with high mortality and low success rates for interventions (~20-30% Ph2 hit rate historically). Primary endpoint—AUC of time-corrected creatinine clearance Days 1-8—is a powered continuous surrogate for kidney recovery, superior to binary measures, using urine/serum creatinine and volume for precision. Patient population well-defined (hospitalized SA-AKI), likely n~250 for adequate power. Novartis sponsor ensures strong operational execution, low site/disclosure risks. Primary completion 36 days past (data likely locked), status active-not-recruiting signals imminent readout. No prior data in summary, but Ph2b advancement implies positive early signal. Risks: AKI creatinine variability, sepsis confounders, single-dose durability unproven. Balanced design yields ~37% probability of positive primary (stat sig dose-response).

This Phase 2 trial for TIN816 in sepsis-associated AKI is high-risk. The primary endpoint is a complex pharmacokinetic surrogate (creatinine clearance AUC), not a hard clinical outcome. The drug has a novel mechanism (p53/Mdm2), but translating that to clinical benefit in sepsis is notoriously difficult. The sponsor is Novartis, which has a strong track record, but the failure rate in sepsis trials is historically very high (>70%). Given the high failure rate in this indication, the base rate suggests a low probability of success.

TIN816 targets sepsis-associated AKI, a high-unmet-need indication with no approved therapies. Phase 2b design tests three single doses versus placebo with creatinine clearance AUC1-8 as primary endpoint—a physiologically relevant but surrogate measure. Novartis is an experienced sponsor with strong operational execution. However, sepsis-AKI trials historically show high placebo response and heterogeneity. The study completed primary completion 36 days ago but remains 'Active Not Recruiting,' suggesting data lock or analysis ongoing without early stopping for futility or overwhelming efficacy. Single-dose design limits exposure duration. No prior Phase 2a data disclosed. Disclosure risk is moderate—Novartis typically announces material clinical data. Endpoint is not registrational; even positive results require Phase 3 confirmation. Base rate for Phase 2 success in AKI indications is ~35-40%.

The CLEAR-AKI trial (NCT05996835) is a Phase 2b dose-finding study in sepsis-associated acute kidney injury (SA-AKI). SA-AKI is a notoriously difficult indication with a long history of clinical trial failures, including late-stage assets like ilofotase alfa and ANG-3777. TIN816 is a novel CD39 recombinant protein intended to hydrolyze extracellular ATP/ADP to dampen inflammation. A prior Phase 2a study of TIN816 (n=20) demonstrated safety but was underpowered for efficacy, and biomarker results were limited by high inter-patient variability and placebo effects. In this Phase 2b trial, the primary endpoint is the area under the time-corrected creatinine clearance curve over Days 1-8. Measuring creatinine clearance in critically ill ICU patients is subject to extreme noise from fluid shifts, renal replacement therapy, and heterogeneous sepsis presentations. Even with 320 patients randomized 3:1:1:3, powering for statistical significance on this surrogate endpoint against placebo is challenging. Although having three dose arms provides multiple shots on goal, the fundamental biological and operational hurdles of SA-AKI research make the intrinsic probability of clear positive results relatively low. We estimate the likelihood of a positive outcome at roughly 30 percent.

The Phase 2b study investigating TIN816 in sepsis-associated acute kidney injury (CLEAR-AKI) has a complex primary endpoint, focusing on the average area under the time-corrected creatinine clearance curve (AUC1-8). Given that the study is still active but not recruiting, and primary completion was expected in February 2026, the data readout is imminent. The indication of sepsis-associated acute kidney injury is severe, and the intervention involves a biological agent. While the study's design seems robust, with a clear focus on dose-response relationship and safety/efficacy, the complexity of the endpoint and the population may introduce variability. Prior data and operational execution will be crucial. The current status and brief summary suggest a potentially positive outcome but with inherent risks. Therefore, a 40% probability of a positive result is estimated, reflecting moderate skepticism due to endpoint complexity and potential variability in patient response.